vaccine design

Synthetic variations of squalene, which is used to boost immune responses, could make vaccines more effective while reducing fisheries for struggling sharks.

Multiple candidates are in Phase 3 clinical trials for older adults and pregnant women, with some getting close to approval in the United States.

Researchers find that small sacks inside lymph nodes contain low proteolytic activity and act as safe havens for antigens.

A method for culturing the infectious stage of the Plasmodium lifecycle could increase malaria vaccine production efficiency by tenfold, study authors say.

Researchers find signatures pre- and post-vaccination that correlate with a more robust immune response. 

Both Pfizer and GSK have shared preliminary data suggesting that their experimental vaccines can protect older adults and newborn infants from the virus.

Low booster rates and immune-evading SARS-CoV-2 variants could spell bad news, experts say. 

Researchers say they’re abandoning the project in its current form—one of several that aims to induce what’s known as mucosal immunity against SARS-CoV-2.

A vaccine strategy involving formulation changes, an initial escalating dose, and a longer wait for booster immunization results in more-effective antibody production against HIV in rhesus monkeys, a study finds.

Researchers report that vaccination against proteins found on profibrotic cells reduced liver and lung fibrosis in laboratory rodents.

The shift is likely to add to an ongoing shortage of primates used in labs, which could slow progress in future COVID-19 vaccine development and other areas.

How scientists aim to induce an immune response against addictive drugs

Researchers are turning to the immune system for help in treating addiction and preventing overdose.

Dozens of intranasally delivered vaccines targeting SARS-CoV-2 are in development. Could they pave the way for widespread nasal vaccination in the future?

The results could help guide the design of new vaccines for the disease.

Canada has ordered 76 million doses of Covifenz, the main ingredient of which was manufactured in the leaves of a tobacco relative.